Botanix Pharmaceuticals - New dermatological and antimicrobial agents
Botanix Pharmaceuticals is a clinical-stage biotech company focused on the development of novel treatments for common skin conditions. Its approach combines synthetic cannabidiol (CBD) and a patented skin delivery technology, Permetrex, for which Botanix has an exclusive licence in dermatology. After demonstrating encouraging human safety data in Phase I/II, the company has a busy pipeline for 2022, with a Phase IIb antimicrobial trial due to commence in Q122 and a Phase Ib/II trial for rosacea already underway, along with plans for Phase III trials in acne and Phase IIb studies in atopic dermatitis. Key to its success will be continued clinical validation of the efficacy of CBD in humans in the chosen indications.Botanix Pharmaceuticals is a pharmaceutical company. Co. is engaged in developing prescription products which to treat serious skin diseases including acne, psoriasis and atopic dermatitis, by utilising a novel drug delivery technology (known as Permetrex™) to deliver an active drug into the affected skin. Co.'s product for acne, which under development, utilises a synthetic form of a natural plant extract (known as cannabidiol) which for a range of diseases, to treat epilepsy, pain and arthritis (amongst other indications).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.